SB Tempus

SB Tempus is a joint venture established between SoftBank Group and Tempus AI to bring advanced AI-driven precision medicine to the Japanese market. The company leverages Tempus AI's extensive library of clinical and molecular data to provide genomic testing and data analysis services for healthcare providers and pharmaceutical companies. By integrating genetic sequencing with clinical records, SB Tempus aims to personalize treatment plans for patients with cancer and other life-threatening diseases. The venture also supports drug discovery and development by providing researchers with data-driven insights into patient populations and treatment efficacy.